Global Lentiviral Vector Market, By Component (Lentiviral promoter, Lentiviral fusion tags, Lentivirus packaging systems and Other), Type (Product and Services), Generation (4th-generation, 3rd-generation, 2nd-generation and 1st-generation), Workflow (Upstream Processing And Downstream Processing), Delivery Method (In Vivo and Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease And Other), Application (Gene Therapy And Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) and Academic/Research Institutes) – Industry Trends and Forecast to 2030.
Lentiviral Vector Market Analysis and Size
Growing geriatric population and demand for vaccine development during the Covid-19 emergence effectively aid the growth of the lentiviral vector market. Strategic initiatives by major market players, as well as increased funding for genomics, provide opportunities for the lentiviral vector market to grow.
Data Bridge Market Research analyses that the lentiviral vector market which is USD 10.30 million in 2022, is expected to reach USD 25.32 million by 2030, at a CAGR of 11.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lentiviral Vector Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Component (Lentiviral promoter, Lentiviral fusion tags, Lentivirus packaging systems and Other), Type (Product and Services), Generation (4th-generation, 3rd-generation, 2nd-generation and 1st-generation), Workflow (Upstream Processing And Downstream Processing), Delivery Method (In Vivo and Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease And Other), Application (Gene Therapy And Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) and Academic/Research Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Cobra Biologics Limited (U.K.), Sirion-Biotech GmbH (Germany), Merck KGaA (Germany), FinVector Oy (Finland), Oxford Biomedica (U.K.), OriGene Technologies, Inc. (U.S.), Sino Biological Inc. (China), Cell Biolabs, Inc. (U.S.), Batavia Biosciences B.V. (Netherlands), Lonza (Switzerland), GENEMEDI (China), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (U.S.), Waisman Biomanufacturing (U.S.), and Cytiva (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lentiviral vectors (LV) are effective vehicles for gene transfer in mammalian cells because of their ability to stably express a gene of interest in both non-dividing and dividing cells. Lentiviruses are human and animal pathogens with long incubation periods and persistent infection. The time between the initial infection and the appearance of the first symptoms can be months or years. Molecular biologists frequently use viral vectors to deliver genetic material into cells. The procedure can be performed in vivo (within a living organism) or cell culture (in vitro). Viruses have evolved specialized molecular mechanisms to efficiently transport their genomes inside the cells they infect.
Lentiviral Vector Market Dynamics
Drivers
- Increasing research and development activities
Various manufacturers are conducting R&D for novel lentiviral gene therapies, which is expected to drive growth in the global lentiviral vectors market. For instance, AVROBIO, Inc., a clinical-stage gene therapy company, presented pre-clinical data for AVR-RD-03 for Pompe disease on May 14, 2020. The research demonstrated the efficacy of lentiviral gene therapy for Pompe disease manifestations in the muscle and central nervous system (CNS).
- Increasing agreements and collaborations
The lentiviral vectors market is expected to grow due to key players focusing on various inorganic growth strategies such as agreements and collaborations. For instance, bluebird bio, Inc. signed a licence agreement with Novartis Pharma AG in May 2017. Novartis will non-exclusively licence certain bluebird patent rights related to lentiviral vector technology in order to develop and commercialise oncology therapies.
Opportunities
- Lentiviral vector demand for t cell engineering for cancer treatment surging
Lentiviral vectors have already been helpful in forming gene-modified cell-based therapies, particularly T cell therapies. Such vectors are also used to deliver Chimeric Antigen Receptors (CARs) or cloned T-cell receptors to mature T cells to induce anti-cancer immunity. The FDA approved the first genetically engineered cellular therapy using lentiviral vectors after CAR T-cell therapies generated with lentiviral vectors demonstrated significant clinical efficacy in patients with B-cell malignancies. Lentiviral vectors have changed and evolved alongside CAR T-cell therapy, and they are now demonstrating their full potential as an alternative therapy and a powerful, supplemental tool in the treatment of a broader range of cancers.
Restraints/Challenge
- Lack of scalability and downstream purification
The lack of scalability and downstream purification limitations of lentiviral vectors may impede the future growth of a lentiviral vector market. Strategic initiatives by major market players and increased funding for genomics provide opportunities for the global lentiviral vector market to grow. The stringent regulatory policies and side effects associated with lentiviral vector products pose a challenge to market growth in the future.
This lentiviral vector market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lentiviral vector market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Lentiviral Vector Market
In March 2020, the US Food and Drug Administration (FDA) issued guidelines for conducting clinical trials of medical products during the COVID-19 public health emergency. On July 2, 2020, the guidelines were updated again. The FDA guidelines include general considerations to assist sponsors and researchers in ensuring the safety of trial participants, compliance with good clinical practise (GCP), and minimising the risks of trial integrity during the COVID-19 public health emergency. The guidelines' appendix also provided answers to some general questions about conducting clinical trials during the COVID-19 public health emergency that the FDA had received from various sponsors and researchers.
Recent Developments
- In 2020, Waisman Biomanufacturing entered into a strategic partnership with the California-based biotech company GigaGen to develop a new drug to treat and prevent COVID-19. This strategic partnership formed by the company will increase the use of development and testing of new types of drugs by Waisman Biomanufacturing, resulting in increased market awareness of its services.
- In 2021, Oxford Biomedica signs a new three-year Development & Supply Agreement with Boehringer Ingelheim to manufacture and supply viral vectors. This agreement is expected to boost the company's sales growth in the coming years.
Global Lentiviral Vector Market Scope
The lentiviral vector market is segmented on the basis of component, type, generation, workflow, delivery method, disease indication, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Component
- Lentiviral promoter
- Lentiviral fusion tags
- Lentivirus packaging systems
- Other
Type
- Product
- Services
Generation
- 4th-generation
- 3rd-generation
- 2nd-generation
- 1st-generation
Delivery Method
- In Vivo
- Ex Vivo
Disease Indication
- Cancer
- Genetic Disorders
- Infectious Diseases
- Veterinary Disease
- Other
Application
- Gene Therapy
- Vaccinology
End User
- Biotechnology Companies
- Pharmaceutical Companies
- Contract Research Organizations Contract Development
- Manufacturing Organization (CDMO)
- Academic/Research Institutes
Workflow
- Upstream
- Plasmid Manufacturing
- Cell Expansion
- Plasmid Transfection and Viral Vector Production
- Downstream
- Purification
- Fill and finish
Lentiviral Vector Market Regional Analysis/Insights
The lentiviral vector market is analyzed and market size insights and trends are provided by country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the lentiviral vector market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lentiviral vector market due to the presence of major market players and increased technological advancement in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The lentiviral vector market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lentiviral vector market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lentiviral vector market. The data is available for historic period 2011-2021.
Competitive Landscape and Lentiviral Vector Market Share Analysis
The lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lentiviral vector market.
Some of the major players operating in the lentiviral vector market are:
- Cobra Biologics Limited (U.K.)
- Sirion-Biotech GmbH (Germany)
- Merck KGaA (Germany)
- FinVector Oy (Finland)
- Oxford Biomedica (U.K.)
- OriGene Technologies, Inc. (U.S.)
- Sino Biological Inc. (China)
- Cell Biolabs, Inc. (U.S.)
- Batavia Biosciences B.V. (Netherlands)
- Lonza (Switzerland)
- GENEMEDI (China)
- Takara Bio Inc. (Japan)
- Thermo Fisher Scientific Inc. (U.S.)
- Waisman Biomanufacturing (U.S.)
- Cytiva (U.S.)
SKU-